Clinical comparison between paclitaxel liposome (Lipusu®) and paclitaxel for treatment of patients with metastatic gastric cancer

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 4, 2013, Pages 2591-2594

  Xu, Xu ^a,b   Wang, Lin ^a,b   Xu, Huan Qin ^b   Huang, Xin En ^a   Qian, Ya Dong ^b   Xiang, Jin ^a  

^a JIANGSU CANCER HOSPITAL   (China)

^b GaoGang People Hospital   (China)

Author keywords

Adverse reactions; Combined chemotherapy; Grast cancer; Paclitaxel liposomes; Pactitaxel

Indexed keywords

EID: 84880282936     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.4.2591     Document Type: Article

References (38)

1. Belotti D, Vergani V, Drudis T, et al (1996). Themicrotubuleaffecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res, 2, 1843-9.
2. Bookman MA, Kloth DD, Kover PE, et al (1997). Shortcourse intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol, 8, 611-4.
3. Chen Q, Zhang Q, Liu J, et al (2003). Multi-center prospective randomized trial on paclitaxel liposome and traditional taxol in the treatment of breast cancer and non small-cell lung cancer. Chin J Oncol, 25, 190-2.
4. Drummond DC, Meyer O, Hong K, et al (1999). Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev, 51, 691-743.
5. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.
6. Gao LL, Huang XE, Zhang Q, et al (2011). A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.
7. Gong P, Huang XE, Chen CY, et al (2012). Comparison on complications of peripherally inserted central catheters by ultrasound guide or conventional method in cancer patients.Asian Pac J Cancer Prev, 13, 1873-5.
8. Huang XE, Li CG, Li Y, et al (2011). Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a phase II trial. Asian Pac J Cancer Prev, 12, 2797-800.
9. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
10. Jiang Y, Huang XE, Yan PW, et al (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 11, 1059-62.
11. Kobayashi M, Tsuburaya A, Nagata N, et al (2006). A feasibility study of sequential paclitaxel and S-1 (PTX/S-1) chemotherapy as postoperative adjuvant chemotherapy for advanced gastric cancer. Gastric Cancer, 9,114-9.
12. Kong Fh, Dong Qf, Cao X (2007). Effect of paclitaxel combined with cisplatin in treatment of non small cell lung cancer. Pract J Cancer, 22, 513-4.
13. Kucukzeybek Y, Dirican A, Erten C, et al (2012). Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer. Asian Pac J Cancer Prev, 13, 2771-4.
14. Li CG, Huang XE, Li Y (2011). Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pac J Cancer Prev, 12, 487-90.
15. Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of OxyContin® administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8.
16. Li CG, Huang XE, Xu L, et al (2012). Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients. Asian Pac J Cancer Prev, 13, 301-4.
17. Li Y, Yan PW, Huang XE, et al (2011). MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 12, 2405-9.
18. Liu W, Li SY, Huang XE, et al (2012). Inhibition of tumor growth in vitro by a combination of extracts from rosa roxburghii tratt and fagopyrum cymosum. Asian Pac J Cancer Prev, 13, 2409-14.
19. Luo J, Wu FY, Li AW, et al (2012). Comparison of vinorelbine, ifosfamide and cisplatin (NIP) and etoposide and cisplatin (EP) for treatment of advanced combined small cell lung cancer (cSCLC) patients: a retrospective study. Asian Pac J Cancer Prev, 13, 4703-6.
20. Scialli AR, Waterhouse TB, Desesso JM, et al (1997). Protective effect of liposome encapsulation on paclitaxel developmental toxicity in the rat. Teratology, 56, 305-10.
21. Sharma A, Straubinger RM (1994). Novel taxol formulations: preparation and characterization of taxol-containing liposomes. Pharm Res, 11, 889-96.
22. Sharma D, Chelvi TP, Kaur J, et al (1996). Novel taxol formulation: polyvinylpyrrolidone nanoparticle-encapsulated taxol for drug delivery in cancer therapy. Oncol Res, 8, 281-6.
23. Shu J, Li CG, Liu YC, et al (2012). Comparison of serum tumor associated material (TAM) with conventional biomarkers in cancer patients. Asian Pac J Cancer Prev, 13, 2399-403.
24. Szebeni J, Muggia FM, Alving CR (1998). Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst, 90, 300-6.
25. Treat J, Damjanov N, Huang C, et al (2001). Liposomal encapsulated chemotherapy: preliminary results of a phase I study of a novel liposomal paclitaxel. Oncology, 15, 44-8.
26. Van Zuylen L, Karlsson MO, Verweij J, et al (2001). Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother Pharmacol, 47, 309-18.
27. Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6.
28. Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of Endostar® combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.
29. Xu JW, Li CG, Huang XE, et al (2011). Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases. Asian Pac J Cancer Prev, 12, 985-7.
30. Xu T, Xu ZC, Zou Q, Yu B, Huang XE (2012). P53 Arg72Pro Polymorphism and Bladder Cancer Risk-Meta-analysis Evidence for a Link in Asians but not Caucasians. Asian Pac J Cancer Prev, 13, 2349-54.
31. Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pac J Cancer Prev, 11, 1115-8.
32. Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev, 12, 2291-4.
33. Yang A, Li J, Xu H, et al (2006). A study on antitumor effect of liposome encapsulated paclitaxel in vivo and in vitro. Bull Chin Cancer, 15, 862-4.
34. Yao CY, Huang XE, Tang JH, et al (2010). Clinical observationson safety of fixed dose rate gemcitabine chemotherapy by intravenous infusion. Asian Pac J Cancer Prev, 11, 553-5.
35. Yu DS, Huang XE, Zhou JN, et al (2012). A Comparative Study on the Value of Anal Preserving Surgery for Aged People with Low Rectal Carcinoma in Jiangsu, China. Asian Pac J Cancer Prev, 13, 2339-40.
36. Zhang LQ, Huang XE, Wang J (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a metaanalysis of 20 populations. Asian Pac J Cancer Prev, 12, 81-5.
37. Zhang XZ, Huang XE, Xu YL, et al (2012). Phase II study on voriconazole for treatment of Chinese patients with malignant hematological disorders and invasive aspergillosis. Asian Pac J Cancer Prev, 13, 2415-8.
38. Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.